13th Dec 2021 20:22
Physiomics PLC - oncology consultant based in Oxford - Secures further deals with existing client Germany's Merck KGaA with an aggregate value of GBP300,000. These projects are expected to be completed over the course of the next six months and will span a range of drug targets and treatment types in both pre-clinical and clinical settings with a particular focus on DNA damage and repair, it says. Physiomics expects further contracts to be signed with Merck over the course of 2022, it adds.
Current stock price: 6.05 pence
Year-to-date change: down 15%
By Arvind Bhunjun; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Physiomics